Alzheimer’s Clinical Trials for Seniors

Our extensive experience in Alzheimer’s clinical trials for seniors, combined with our relationships with leading universities and pharmaceutical companies, supports the advancement of early detection, the slowing of disease progress and our quest to end Alzheimer’s disease.

Research partners include Harvard University, Johns Hopkins University, University of Southern California, Eli Lilly, Eisai, Biogen and many others.

Our Alzheimer’s clinical trials for seniors employ the latest methodologies and are based on the most encouraging theories. By joining other participants, you are helping develop medical treatments as well as breakthrough technologies.

We cover participants’ clinical trial costs, offer access to our other memory care programs and, in some cases, compensation may be available for time and travel.

If you are interested in participating or learning more about our Alzheimer’s clinical trials for seniors, please call 305.514.8710 or email clinicaltrials@miamijewishhealth.org

 


 

CURRENT CLINICAL TRIALS

Study of the efficacy, safety and biomarker effects of alz-801 in subjects with early Alzheimer’s disease and apoe4/4 genotype

  • Name of Study: Alz-801-ad301 (apolloe4)
  • Description of Study: Study of the efficacy, safety and biomarker effects of alz-801 in subjects with early Alzheimer’s disease and apoe4/4 genotype
  • Indication: Early Alzheimer’s Disease
  • Recruiting Participant Age: 50 – 80 years of age
  • Duration of Study: 82 weeks

 

 

Long-Term Nicotine Treatment of Mild Cognitive Impairment

  • Name of Study: MIND Study – Long-Term Nicotine Treatment of Mild Cognitive Impairment. Academia Study, funded by the National Institute on Aging (NIA) and conducted by Vanderbilt University and University of Southern California
  • Description of Study: The purpose of the Memory Improvement through Nicotine Dosing (MIND) Phase II study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with MCI.
  • Indication: Mild Cognitive Impairment or Memory Loss
  • Recruiting Participant Age: 55+ years
  • Duration of Study: 2 years

 

Clinical trial of Dronabinol in Nursing Home patients with severe agitation

  • Name of Study: Dronabinol – Johns Hopkins
  • Description of Study: This is a Phase II placebo-controlled, double-blind randomized clinical trial of Dronabinol in Nursing Home patients with severe agitation – AD.
  • Indication: Alzheimer’s Disease with Agitation
  • Recruiting Participant Age:  18+ years
  • Duration of Study: Approximately 24 weeks (12-week treatment period)

 

An assessment of the safety, tolerability and efficacy of Escitalopram for Agitation in Alzheimer’s Disease

  • Name of Study: S-CitAD – Johns Hopkins
  • Description of Study: This is a Phase II placebo-controlled, masked study, assessing the safety, tolerability and efficacy of Escitalopram for Agitation in Alzheimer’s Disease.
  • Indication: Alzheimer’s Disease with Agitation
  • Recruiting Participant Age: 18 years +
  • Duration of Study: Approximately 24 weeks (12-week treatment period)

 

An assessment of the safety and efficacy of T3D-959 in subjects with Mild to Moderate Alzheimer’s Disease

  • Name of Study: T3D Therapeutics – T3D959
  • Description of Study: This is a Phase II placebo-controlled, double–blind randomized study, assessing the safety and efficacy of T3D-959 in subjects with Mild to Moderate Alzheimer’s Disease.
  • Indication: Mild to Moderate Alzheimer’s Disease
  • Recruiting Participant Age: 50 – 90 years of age
  • Duration of Study: Approximately 24 weeks

 

 

Live Life Better

Contact Us Today